This conference aims to disseminate cutting-edge findings on preclinical neurodegenerative diseases—including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease. The event will provide a unique platform for specialists to come together across disciplines for an authoritative discussion of the methodological, regulatory, and ethical considerations of research in people at asymptomatic states of neurodegenerative disease.

A high-level invited oral program, supplemented by contributed posters, will provide a complete update on the latest research and thinking on the following topics:

• Genetic factors, cellular pathways, and neuronal vulnerability
• Environmental factors, epidemiology, and primary prevention
• Biomarkers and early diagnosis
• Prevention through therapeutics
• Trials; regulatory and ethical considerations

The event will also have a translational focus, exploring genetic susceptibility, epidemiology and risk factors, neuronal vulnerability, biomarkers and early diagnosis, and disease prevention in healthy individuals with both pharmacological and non-pharmacological interventions.